| 产品描述: | TGFβRI/ALK5 选择性抑制剂;TGFβRI/ALK5 Selective Inhibitors;;InformationLY 3200882 is a potent, highly selective inhibitor ofTGF-β receptor type 1 (TGFβRI). It potently inhibits TGFβ mediated SMAD phosphorylation in vitro in tumor and immune cells and in vivo in subcutaneous tumors in a dose dependent fashion.TargetsTGFβRIIn vitroLY3200882 inhibits various pro-tumorigenic activities. LY3200882 potently inhibits TGFβ mediated SMAD phosphorylation in vitro in tumor and immune cells and in vivo in subcutaneous tumors in a dose dependent fashion. In in vitro immune suppression assays, LY3200882 has shown the ability to rescue TGFβ1 suppressed or T regulatory cell suppressed naïve T cell activity and restore proliferation. It acts as an immune modulatory agent.In vivoIn preclinical tumor models, LY3200882 showed potent anti-tumor activity in the orthotopic 4T1-LP model of triple negative breast cancer and this activity correlated with enhanced tumor infiltrating lymphocytes in the tumor microenvironment. Durable tumor regressions in the orthotopic 4T1-LP model were observed and rechallenge of congenic tumors resulted in complete rejection in all mice. LY3200882 has shown anti-metastatic activity in an experimental metastasis tumor model (intravenous EMT6-LM2 model of triple negative breast cancer). In addition, LY3200882 shows combinatorial anti-tumor benefits with checkpoint inhibition (anti-PD-L1) in the syngeneic CT26 model. |
| 靶点: |
IC50: 38.2 nM (TGF-β receptor type 1 (ALK5)) |
| 体内研究: |
LY3200882 (60 mg/kg;口服管饲;每日两次;持续 21 天;BALB/C 雌性小鼠) 治疗可显著延缓 CT26 模型中的肿瘤生长。 LY3200882 以剂量依赖性方式强效抑制皮下肿瘤中 TGFβ 介导的 SMAD 磷酸化。 LY3200882 在实验转移性肿瘤模型 (三阴性乳腺癌静脉注射 EMT6-LM2 模型) 中表现出体内抗转移活性。 |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.296 ml |
11.481 ml |
22.961 ml |
| 5 mM |
0.459 ml |
2.296 ml |
4.592 ml |
| 10 mM |
0.23 ml |
1.148 ml |
2.296 ml |
| 50 mM |
0.046 ml |
0.23 ml |
0.459 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |